Brain Development Research Consortium

At a Glance
  • Status: Active Consortium
  • Year Launched: 2014
  • Initiating Organization: Astellas, Eli Lilly and Company, Lundbeck, Pfizer, and Roche
  • Initiator Type: Industry
  • Disease focus:
    Brain disorders
  • Location: International


The Lieber Institute for Brain Development and pharmaceutical companies Astellas, Eli Lilly and Company, Lundbeck, Pfizer Inc., and Roche are participating in an early-stage research consortium to analyze ribonucleic acid (RNA), the genomic and epigenetic data obtained from human brains.


This consortium is a bold initiative with the potential to have broad relevance across the spectrum of human brain disorders. By uniting diverse scientists from different sectors, it has created a new model of cooperative research that is designed to accomplish ambitious goals with efficiency and focus.

Astellas, Eli Lilly and Company, Lundbeck, Pfizer, and Roche, as members of the consortium, will seek to convert basic scientific findings into new treatment options for people living with developmental brain disorders.

Consortium History

March 2014: Consortium announced

Sponsors & Partners


Eli Lilly and Company

Lieber Institute for Brain Development


Pfizer Inc.


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.